Imatinib-resistance without BCR/ABL Point Mutation in Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a myeloproliferative bone marrow neoplasm that occurs because of a fusion gene called BCR-ABL1. Imatinib -the inhibitor of this fusion geneis the target therapy in CML. But unfortunately, resistance against imatinib occurs in some patients. In September 2019 47-year...

Full description

Bibliographic Details

Published in:	Caucasian Medical Journal
Main Author:	Aytan Shirinova
Format:	Article
Language:	English
Published:	Azerbaijan Gastroenterology and Invasive Endoscopy Society 2024-03-01
Subjects:	imatinib-resistance cml abl1 domain mutations
Online Access:	https://caucasianmedj.com/articles/imatinib-resistance-without-bcrabl-point-mutation-in-chronic-myeloid-leukemia/doi/cmj.galenos.2024.36855